Pascal Soriot | |
|---|---|
 Soriot in 2019 | |
| Born | Pascal Claude Roland Soriot 23 May 1959 France |
| Citizenship |
|
| Education | École nationale vétérinaire d'Alfort HEC Paris |
| Occupation | Businessman |
| Years active | 1982–present |
| Title | CEO, AstraZeneca |
| Term | 2012– |
| Children | 2 |
| Honours | Knight Bachelor |
Sir Pascal Claude Roland Soriot (born 23 May 1959) is a French-born Australian businessman and chief executive officer (CEO) of the British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca. [1]
Pascal Soriot was born in France on 23 May 1959. [2] His father died when he was 20. [3]
He studied veterinary medicine at the École nationale vétérinaire d'Alfort at Maisons-Alfort in Paris. [2] He later obtained an MBA at HEC Paris. [1]
In April 1986, he joined Roussel Uclaf (formerly France's second largest pharmaceutical company, until bought by Hoechst AG in 1997) as a salesman in Australia. [2] [4] In 1996, he became General Manager of Hoechst Marion Roussel in Australia, moving to Tokyo in April 1997. [5]
In 2000 he moved to Aventis in America, becoming chief operating officer of Aventis USA in 2002, which became Sanofi Aventis USA in 2004. [6] [7]
He joined Roche in 2006 as head of marketing. [8] From April 2009 to 2010, he was chief executive of the Roche subsidiary Genentech. He rejoined Roche Pharma AG in 2010 as chief operating officer. [9]
In August 2012 he was named as the new chief executive of AstraZeneca, [10] the world's fifth largest pharmaceutical company, when aged 53. He took up the post on 1 October 2012. [11] [12]
In July 2017, it was reported that Soriot would become the next CEO of Israel-based Teva Pharmaceutical Industries, succeeding Erez Vigodman, though this was soon denied. [13] [14] [15]
In September 2018, he made headlines commenting on his pay of £9.4m in salary and bonuses. 'The truth is I’m the lowest-paid CEO in the whole industry', he said. 'It is annoying to some extent. But at the end of the day it is what it is.' [16]
In 2023, Soriot was the highest paid CEO of the major European pharmaceutical companies, as he earned $21.3 million.That was a nearly 12% increase over 2022. [17]
He is married and has two children. [18] He has three brothers, all of whom are doctors. [3]
Soriot was knighted in the 2022 Birthday Honours for services to UK life sciences and the response to COVID-19. [19] He qualifies for a substantive knighthood rather than an honorary one by virtue of being an Australian citizen. [20]
He counts cycling, horse riding and skiing as hobbies. [21]
Pharmaceutical Research and Manufacturers of America, formerly known as the Pharmaceutical Manufacturers Association, is a trade group representing companies in the pharmaceutical industry in the United States. Founded in 1958, PhRMA lobbies on behalf of pharmaceutical companies. PhRMA is headquartered in Washington, DC.
Hoechst AG was a German chemicals, later life sciences, company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999. With the new company's 2004 merger with Sanofi-Synthélabo, it became a subsidiary of the resulting Sanofi-Aventis pharmaceuticals group.
AstraZeneca plc (AZ) is a British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.
Judith Carol Lewent is a business executive who served as chief financial officer of Merck & Co. from 1990 until her retirement from the company in 2007. Since her retirement from Merck, she has continued to serve on multiple corporate boards, including the boards of GlaxoSmithKline, Thermo Fisher Scientific and Motorola Solutions. She also served on the board of Purdue Pharma until her departure from the company in 2014.
King Pharmaceuticals, is a pharmaceutical company, a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world's 39th largest pharmaceutical company. On October 12, 2010, King was acquired by Pfizer for $14.25 per share. King produced a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant. King Pharmaceuticals operated manufacturing facilities in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin. They employed approximately 2,700 people including a sales force of over 1,000 individuals.
Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi.
Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.
Apotex Inc. is a Canadian pharmaceutical corporation. Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries. Apotex manufactures and distributes generic medications for a range of diseases and health conditions that include cancer, diabetes, high cholesterol, glaucoma, infections and blood pressure.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed briefly by US-based Pfizer. Teva regained its market leader position once Pfizer spun off its generic drug division in a merger with Mylan, forming the new company Viatris at the end of 2020. Overall, Teva is the 18th largest pharmaceutical company in the world.
Rhône-Poulenc was a French chemical and pharmaceutical company founded in 1928. In 1999, it merged with Hoechst AG to form Aventis. As of 2015, the pharmaceutical operations of Rhône-Poulenc are part of Sanofi and the chemicals divisions are part of Solvay group and Bayer Crop Science.
John M. Gregory is an American businessman. He was former CEO of King Pharmaceuticals, Inc. and resides in Bristol, Tennessee. In addition to founding King Pharmaceuticals in 1993, Gregory has founded several other notable business ventures including SJ Strategic Investments and Leitner Pharmaceuticals. Gregory has also made major investment outside of the pharmaceutical industry, such as his investments within the privately held United Coal Company located in southwest Virginia and Adams Golf with U.S. corporate offices in Texas. Most recently, Gregory, along with other family members, began Gregory Pharmaceutical Holdings Inc. which include pharmaceutical contract manufacturing company, UPM Pharmaceuticals, and NFI Consumer Products which includes the Blue-Emu brand of products.
Marion Merrell Dow and its predecessor Marion Laboratories was a U.S. pharmaceutical company based in Kansas City, Missouri, from 1950 until 1996.
Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression. Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects. However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.
Paul Hudson is a British businessman, and the chief executive (CEO) of Sanofi, the world's fifth largest pharmaceutical company by prescription drug sales.
| International | |
|---|---|
| National | |
